Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group

[1]  M. Thill,et al.  [The 20-year results of 5‑year hormone therapy in breast cancer : Early Breast Cancer Trialists' Collaborative Group (EBCTCG)]. , 2018, Der Internist.

[2]  H. Gómez,et al.  Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  V. Georgoulias,et al.  Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  L. V. van't Veer,et al.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.

[5]  M. Buyse,et al.  Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  I. Boukovinas,et al.  Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG) , 2014, Breast Cancer Research and Treatment.

[7]  S. Paik,et al.  Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Gelber,et al.  Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Yuanyuan Zhang,et al.  Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials. , 2012, Breast.

[10]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.

[11]  Jong-Hyeon Jeong,et al.  Breast cancer adjuvant therapy: time to consider its time-dependent effects. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Perez,et al.  Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. , 2010, The New England journal of medicine.

[13]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[14]  M. Krzakowski,et al.  Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Glas,et al.  Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer , 2016 .

[16]  D. Mavroudis,et al.  Paclitaxel and docetaxel in the treatment of breast cancer. , 2008, Expert opinion on pharmacotherapy.